Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

publication in Clinical Cancer Research highlighting bavituximab's ability to target tumor blood vessels with excellent specificity, and the acceptance last week of an abstract discussing patient data from the Cotara dosimetry trial for presentation at the 2008 ASCO Annual Meeting. We anticipate additional high profile scientific publications and presentations in the coming months while we continue making good progress in advancing our trio of Phase II bavituximab cancer trials, the two ongoing Cotara clinical trials and the trial of bavituximab in HCV patients co-infected with HIV. We look forward to a steady flow of news from these multiple activities in the coming months."

Recent Highlights

Bavituximab Anti-Cancer Program: The company launched the Phase II cancer clinical program for bavituximab during the quarter and achieved a number of other clinical and preclinical advancements.
-- Initiated patient dosing in a Phase II combination therapy trial of

bavituximab and docetaxel in patients with advanced breast cancer

within 14 days of study initiation.

-- Received regulatory approval to begin two additional Phase II

bavituximab combination therapy trials -- one in combination with

carboplatin and paclitaxel in patients with advanced breast cancer and

another in combination with carboplatin plus paclitaxel in patients

with non-small cell lung cancer (NSCLC). Both trials are preparing to

begin enrolling patients shortly.

-- A bavituximab cancer investigator presented data at a leading

scientific meeting on anti-angiogenic agents -- the 10th Annual

International Symposium on Anti-Angiogenic Agents (Angio 2008) --

highlighting the positive clinical experience to date with

bavituximab.

-- A preclinical study published in Clinical Cancer Research confirmed

bavituximab's ability to target tumor blood ves
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... N.C. , Sept. 17, 2014  The In ... topics that will be featured at the conference, which ... Center on December 3 and 4, 2014. Researchers, students, ... invited to hear the following: KEYNOTE ... San Diego Skaggs School of Pharmacy ...
(Date:9/17/2014)... Shimadzu Scientific Instruments introduces ... which offers a powerful separation method for ... provides a new level of knowledge and ... to scientists analyzing pharmaceutical impurities, proteins, lipids, ... Comprehensive 2D-LC combines two independent separation modes ...
(Date:9/17/2014)... 2014 A biodegradable polymer can ... as bacteria, fungi, and algae into smaller units ... inorganic compounds, carbon dioxide, and humus in a ... and improved costs, biodegradable polymers are proving to ... to conventional polymers. Primary factors that are responsible ...
(Date:9/17/2014)... , Sept. 17, 2014 BioClinica®, Inc., a ... Solutions, today announced three of its experts are speaking ... Clinical Data Management to be held September 28 to ... . The Company also announced the innovative Compass ... quality in clinical trials acquired earlier this year, is ...
Breaking Biology Technology:In Silico Drug Discovery Conference Announces Speakers and Topics 2In Silico Drug Discovery Conference Announces Speakers and Topics 3In Silico Drug Discovery Conference Announces Speakers and Topics 4In Silico Drug Discovery Conference Announces Speakers and Topics 5In Silico Drug Discovery Conference Announces Speakers and Topics 6In Silico Drug Discovery Conference Announces Speakers and Topics 7Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3
... N.J., Sept. 22, 2011 Parent ... in the United States focused on finding a cure for ... awarded Tejvir S. Khurana, MD, PhD, Professor of Physiology at ... Duchenne Grant for $98,000. (Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO ...
... PrimeraDx today announced that Albert Luderer has been appointed ... CEO Matthew McManus commented:  "We are excited to have Al ... launched the ICE Plex System, which is the first ... qPCR, and Al brings many years of experience in the ...
... Neogen Corporation (NASDAQ: NEOG ) has developed ... considered by many to be the most potent, naturally-occurring carcinogen. ... wide range of commodities, including corn. Because it is a ... 100 countries have established regulatory limits for aflatoxin in commodities ...
Cached Biology Technology:Parent Project Muscular Dystrophy Awards End Duchenne Grant to University of Pennsylvania's Dr. Tejvir S. Khurana 2Parent Project Muscular Dystrophy Awards End Duchenne Grant to University of Pennsylvania's Dr. Tejvir S. Khurana 3PrimeraDx Appoints Albert A. Luderer to its Board of Directors 2Neogen Launches Fully Quantitative Lateral Flow Test for Aflatoxin 2
(Date:9/17/2014)... human retinoblastoma protein gene are a leading cause of ... to fruit fly eyes to unlock the secrets of ... featured on the cover of the current issue of ... University researchers provide the first detailed examination of a ... human cancer gene, said Irina Pushel, MSU undergraduate and ...
(Date:9/17/2014)... University] After decades of decline, grasses have returned ... the eye, the marsh in those places seems healthy ... key service of the marsh coastal protection ... the ecosystem function hasn,t come back," said ecologist Mark ... of the study in the journal Biological Conservation ...
(Date:9/17/2014)... social behavior by studying nonhuman mammals and primates, but ... their unusually large brains relative to their body size ... environment---not merely in a large population of cooperating creatures, ... setting of alliances and competitors. The same is true ... social carnivores, like hyenas and lions. , A new ...
Breaking Biology News(10 mins):Abnormal properties of cancer protein revealed in fly eyes 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Being social: Learning from the behavior of birds 2
... deadline for the European Congress on Osteoporosis & Osteoarthritis ... Thursday January 17, 2013. SUBMIT YOUR ABSTRACT ... yet registered?, Register now for Europe,s largest and most ... April 17-20, 2013. Featuring renowned speakers, ...
... With $14 million from the William & Nancy ... of Orange County, UC Irvine is helping lead the ... 88 children in the U.S. autism., The funding ... Southern California, which will provide unparalleled access to assessment, ...
... ornamental fish industry faces a global problem with antibiotic ... for fish diseases may not work when needed ... antibiotic-resistant bacteria. The risk to humans is probably ... compromised immune systems, researchers said, although transmission of disease ...
Cached Biology News:UCI research turns the corner on autism 2UCI research turns the corner on autism 3Ornamental fish industry faces increasing problems with antibiotic resistance 2Ornamental fish industry faces increasing problems with antibiotic resistance 3
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
D-biotin *50 mM aqueous solution* Secondary Detection Biotin–Avidin Detection Reagents Other...
Green Standard is fluorescein....
Human/Mouse/Rat LAR Affinity Purified PAb...
Biology Products: